Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders.
Philadelphia chromosome-negative myeloproliferative disorders
covert brain infarcts
endothelial dysfunction
hematology
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
21 Dec 2021
21 Dec 2021
Historique:
received:
19
11
2021
revised:
10
12
2021
accepted:
17
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
Philadelphia chromosome-negative myeloproliferative disorders (Ph-negative MPD) are a rare group of hematological diseases, including three distinct pathologies: essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). They most often manifest with thrombotic complications, including cerebrovascular events. Covert brain infarcts (CBIs) are defin ed as predominantly small ischemic cerebral lesions that are detected using magnetic resonance imaging (MRI) in the absence of clinical stroke events. The relationship between MPD and CBIs remains unclear. Included in the study were 103 patients with the diagnosis of Ph-MPD (according to WHO 2016 criteria) (median age-47 (35; 54) years; 67% female). In total, 38 patients had ET, 42 had PV, and 23 had PMF. They underwent clinical examination, routine laboratory analyses (complete blood count), brain MRI, ultrasound carotid artery, flow-mediated dilatation (as a measure of endothelial dysfunction-FMD). Overall, 23 patients experienced an ischemic stroke (as per MRI and/or clinical history), of which 16 (15.5%) could be classified as CBIs. The rate of CBIs per MPD subtype was statistically non-significant between groups ( CBIs are common in patients with Ph-negative MPD. Arterial hypertension and carotid atherosclerosis were not associated with CBIs in this group of patients. The most significant factors in the development of CBIs were endothelial dysfunction (as measured by FMD) and high hemoglobin levels. Patients with Ph-negative MPD and CBIs were older and had more prevalent endothelial dysfunction.
Sections du résumé
BACKGROUNDS AND PURPOSE
OBJECTIVE
Philadelphia chromosome-negative myeloproliferative disorders (Ph-negative MPD) are a rare group of hematological diseases, including three distinct pathologies: essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). They most often manifest with thrombotic complications, including cerebrovascular events. Covert brain infarcts (CBIs) are defin ed as predominantly small ischemic cerebral lesions that are detected using magnetic resonance imaging (MRI) in the absence of clinical stroke events. The relationship between MPD and CBIs remains unclear.
METHODS
METHODS
Included in the study were 103 patients with the diagnosis of Ph-MPD (according to WHO 2016 criteria) (median age-47 (35; 54) years; 67% female). In total, 38 patients had ET, 42 had PV, and 23 had PMF. They underwent clinical examination, routine laboratory analyses (complete blood count), brain MRI, ultrasound carotid artery, flow-mediated dilatation (as a measure of endothelial dysfunction-FMD).
RESULTS
RESULTS
Overall, 23 patients experienced an ischemic stroke (as per MRI and/or clinical history), of which 16 (15.5%) could be classified as CBIs. The rate of CBIs per MPD subtype was statistically non-significant between groups (
CONCLUSIONS
CONCLUSIONS
CBIs are common in patients with Ph-negative MPD. Arterial hypertension and carotid atherosclerosis were not associated with CBIs in this group of patients. The most significant factors in the development of CBIs were endothelial dysfunction (as measured by FMD) and high hemoglobin levels. Patients with Ph-negative MPD and CBIs were older and had more prevalent endothelial dysfunction.
Identifiants
pubmed: 35011753
pii: jcm11010013
doi: 10.3390/jcm11010013
pmc: PMC8745571
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Stroke. 2020 Jan;51(1):2-3
pubmed: 31766981
Eur Heart J. 2019 Aug 7;40(30):2534-2547
pubmed: 31211361
J Neurol Sci. 2020 Sep 15;416:116990
pubmed: 32593885
Blood Rev. 2020 Jul;42:100706
pubmed: 32517877
Thromb Res. 2020 Feb;186:86-92
pubmed: 31927271
Sci Rep. 2020 Jul 10;10(1):11467
pubmed: 32651430
J Clin Neurol. 2021 Apr;17(2):164-175
pubmed: 33835736
JAMA Oncol. 2015 Apr;1(1):97-105
pubmed: 26182311
JAMA. 2004 Jan 28;291(4):427-34
pubmed: 14747499
Blood Cancer J. 2018 Feb 9;8(2):15
pubmed: 29426921
J Am Coll Cardiol. 2002 Jan 16;39(2):257-65
pubmed: 11788217
Angiology. 2020 May;71(5):397-410
pubmed: 32077315
Lancet Neurol. 2007 Jul;6(7):611-9
pubmed: 17582361
J Thromb Thrombolysis. 2021 Jan;51(1):112-119
pubmed: 32578055
Blood Cancer J. 2020 Feb 25;10(2):21
pubmed: 32098944
Stroke. 2019 Aug;50(8):2181-2186
pubmed: 31284847
Clin Appl Thromb Hemost. 2018 Oct;24(7):1102-1108
pubmed: 29683036
Stroke. 2002 Oct;33(10):2376-82
pubmed: 12364724
Radiol Oncol. 2017 Jan 14;51(2):203-210
pubmed: 28740456
Stroke. 2020 Jan;51(1):90-98
pubmed: 31766980
Br J Haematol. 2001 Nov;115(2):354-9
pubmed: 11703335
Stroke. 2017 Feb;48(2):e44-e71
pubmed: 27980126
BMC Med. 2014 Jul 09;12:119
pubmed: 25012298
Stroke. 2020 Aug;51(8):2597-2606
pubmed: 32646332
Hematol Oncol. 2021 Aug;39(3):409-418
pubmed: 33590502
Can J Neurol Sci. 2020 Jul;47(4):456-463
pubmed: 32122431
Mediterr J Hematol Infect Dis. 2020 Jan 01;12(1):e2020008
pubmed: 31934318